NEW YORK, Aug. 13 (GenomeWeb News) - Auvation, a Scottish company that focuses on developing biomarkers for tumors, and ExpressOn Biosystems, another Scottish company that focuses on the development of antisense RNA interference, have forged an agreement to collaborate in developing targets for cancer therapy, Auvation officials announced last week.